RA Capital Management’s Lisata Therapeutics LSTA Stock Holding History

RA Capital Management’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-50,167	Closed	-$399K	–	91
2022 Q2	$399K	Buy	+50,167	New	+$413K	0.01%	88

Other funds holding LSTA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Cook Wealth Raleigh, North Carolina $206M AUM 4.73% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RA Capital Management's LSTA Position: Q3 2022 in Review

RA Capital Management sold out of Lisata Therapeutics (LSTA) in Q3 2022, closing a stake of 50,167 shares — an estimated $399K sold.

RA Capital Management first reported a position in LSTA in Q2 2022 and held it in 1 quarter. The position peaked at $399K in Q2 2022. 22 funds tracked by Wall St. Rank hold LSTA as of Q3 2022.

RA Capital Management reported no remaining Lisata Therapeutics position as of Q3 2022 after selling out during the quarter.
RA Capital Management sold 50,167 Lisata Therapeutics shares in Q3 2022, an estimated $399K.
RA Capital Management first reported a position in Lisata Therapeutics in Q2 2022 and held it in 1 quarter.
RA Capital Management's Lisata Therapeutics position peaked at $399K in Q2 2022.
22 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q3 2022.

Based on RA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.